Navigation Links
Cepheid to Webcast Upcoming Financial Presentations
Date:8/26/2009

SUNNYVALE, Calif., Aug. 26 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.

           Thomas Weisel Partners Healthcare Conference, Boston, MA
           Wednesday, 9 September, 2009, at 8.35 a.m. Eastern Time

           R. W. Baird 2009 Health Care Conference, New York, NY
           Thursday, 10 September, 2009, at 9.30 a.m. Eastern Time

           ThinkEquity Annual Growth Conference, San Francisco, CA
           Wednesday, 16 September, 2009, at 12.45 p.m. Pacific Time

           UBS  Global Life Sciences Conference, New York, NY
           Tuesday, 22 September, 2009, at 2.30 p.m. Eastern Time

Accessing Webcasts

To access the live webcasts for these events, please visit Cepheid's website at www.cepheid.com/investors at least 15 minutes before the schedule start time to download any necessary audio or plug-in software. A replay of the webcast will be available shortly following the presentation and will remain available for at least 90 days.

About Cepheid

Cepheid (Nasdaq: CPHD), based in Sunnyvale, Calif., is an on-demand molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial and biothreat markets. The Company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. Cepheid's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the Company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market.

    CONTACTS:
    For Media Inquiries:                     For Investor Inquiries:
    Jared Tipton                             Jacquie Ross
    Cepheid Corporate Communications         Cepheid Investor Relations
    Tel: (408) 400-8377                      Tel: (408) 400-8329
    jared.tipton@cepheid.com                 investor.relations@cepheid.com


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cepheid Reports 2009 Second Quarter Results
2. Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
3. Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)
4. Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference
5. Cepheid Receives Health Canada License for Xpert(R) HemosIL(R) FII & FV Test
6. Blue Mountain Quality Resources Announces that Cepheid has Selected Blue Mountain Regulatory Asset Manager
7. Cepheid to Webcast Upcoming Financial Presentations
8. Cepheid Announces European Release of First On-Demand Molecular Pre-Surgical Screening Test for Simultaneous Detection of Methicillin-Sensitive and Resistant S. aureus
9. Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
10. Cepheid Reports Fourth Quarter and Full Year 2008 Results
11. Cepheid Receives Health Canada License for First Molecular Diagnostic Test for MRSA and S. aureus Soft Tissue Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ... February 19, 2017 , ... ... healthcare, will join forces with Healthwise ® at HIMSS 2017 ... industry leader in evidence-based health education, technology and services, will demonstrate a voice-powered ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/17/2017)... ... February 17, 2017 , ... Smiles by Seese is ... in Davidson, NC. Dr. Brian Seese leads the practice as a skilled and highly ... one roof. Smiles by Seese serves patients of all ages with excellence in general, ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... -- Summary Provides understanding and access to the ... healthcare companies. ... The Global Allergy Partnering Terms and Agreements since 2010 report ... by the world,s leading healthcare companies. - Trends ... Deals listed by company A-Z, industry sector, stage of development, technology ...
(Date:2/16/2017)... and SCOTTSDALE, Ariz. , Feb. 16, ... Health Information Exchange (HIE), announced today it is partnering with ... HealthInfoNet,s HIE contains 98% of all Maine ... Maine hospitals and over 500 ambulatory care ... Directors, HealthInfoNet plans to deploy Orion Health,s Amadeus , ...
(Date:2/16/2017)... 2017   Spectralink Corporation , the global ... retail, manufacturing and hospitality industries, today announced the ... symbology support features of its PIVOT™:SC (8744) ... The study, conducted by The Tolly Group, showed ... phones with dedicated hardware scanners. Spectralink ...
Breaking Medicine Technology: